Business Description
Viracta Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92765F1084
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.1 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.7 | |||||
Debt-to-EBITDA | -0.43 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -33.7 | |||||
3-Year EPS without NRI Growth Rate | -36.9 | |||||
3-Year FCF Growth Rate | -33.5 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.71 | |||||
9-Day RSI | 41.58 | |||||
14-Day RSI | 43.05 | |||||
6-1 Month Momentum % | 60.95 | |||||
12-1 Month Momentum % | -52.53 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.35 | |||||
Quick Ratio | 1.35 | |||||
Cash Ratio | 1.31 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.9 | |||||
Shareholder Yield % | -27.67 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -158.59 | |||||
ROA % | -73.36 | |||||
ROIC % | -304.56 | |||||
ROC (Joel Greenblatt) % | -7842.3 | |||||
ROCE % | -113.51 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.64 | |||||
Price-to-Tangible-Book | 5.62 | |||||
EV-to-EBIT | -0.37 | |||||
EV-to-EBITDA | -0.38 | |||||
EV-to-FCF | -0.45 | |||||
Price-to-Net-Current-Asset-Value | 6.08 | |||||
Price-to-Net-Cash | 3.32 | |||||
Earnings Yield (Greenblatt) % | -270.27 | |||||
FCF Yield % | -114.86 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Viracta Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.137 | ||
Beta | 0.98 | ||
Volatility % | 159.95 | ||
14-Day RSI | 43.05 | ||
14-Day ATR (€) | 0.029257 | ||
20-Day SMA (€) | 0.755 | ||
12-1 Month Momentum % | -52.53 | ||
52-Week Range (€) | 0.236 - 1.97 | ||
Shares Outstanding (Mil) | 39.27 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Viracta Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Viracta Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Viracta Therapeutics Inc Frequently Asked Questions
What is Viracta Therapeutics Inc(FRA:RYI)'s stock price today?
When is next earnings date of Viracta Therapeutics Inc(FRA:RYI)?
Does Viracta Therapeutics Inc(FRA:RYI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |